Skip to main content

Table 2 Estimated Reporting Rate of All Malignancies and Lymphoma per 100 Patient-years (PY) of Etanercept Exposure

From: Summary of worldwide pediatric malignancies reported after exposure to etanercept

 

4-17 years

18-22 years

 

Worldwide

US

Worldwide

US

Estimated exposure to etanercept (PY) through July 2009

49,716

33,409

33,887

22,349

All malignancies (rate/100 PY)

0.020

0.015

0.024*

0.013*

Lymphoma (rate/100 PY)

0.010

0.009

0.006*

0.004*

  1. *Calculated reporting rate for those age 18-22 years includes only cases with exposure prior to age 19 and does not includes cases with first etanercept exposure at age 19-22.